A simulation study of methods for selecting subgroup‐specific doses in phase 1 trials. (23rd January 2017)

• Record Type: Journal Article
• Authors: Morita, Satoshi; Thall, Peter F.; Takeda, Kentaro
• Is Part Of: Pharmaceutical statistics. Volume 16:Number 2(2017)
• Page Start: 143
• Page End: 156
• Publication Date: 2017-01-23
• Subjects: Bayesian study design -- conditionally independent hierarchical model -- continual reassessment method -- phase 1 clinical trial -- subgroup‐specific dose‐finding; Pharmacy -- Statistical methods -- Periodicals; Pharmacy -- Statistics -- Periodicals; 615.10727
• DOI: 10.1002/pst.1797
• Languages: English
• ISSNs: 1539-1604

Abstract

Abstract : Patient heterogeneity may complicate dose‐finding in phase 1 clinical trials if the dose‐toxicity curves differ between subgroups. Conducting separate trials within subgroups may lead to infeasibly small sample sizes in subgroups having low prevalence. Alternatively, it is not obvious how to conduct a single trial while accounting for heterogeneity. To address this problem, we consider a generalization of the continual reassessment method on the basis of a hierarchical Bayesian dose‐toxicity model that borrows strength between subgroups under the assumption that the subgroups are exchangeable. We evaluate a design using this model that includes subgroup‐specific dose selection and safety rules. A simulation study is presented that includes comparison of this method to 3 alternative approaches, on the basis of nonhierarchical models, that make different types of assumptions about within‐subgroup dose‐toxicity curves. The simulations show that the hierarchical model‐based method is recommended in settings where the dose‐toxicity curves are exchangeable between subgroups. We present practical guidelines for application and provide computer programs for trial simulation and conduct.